 high-dos chemoradiotherapi marrow infus advanc neuroblastoma pediatr oncolog group erratum clin oncol jun pilot protocol pediatr oncolog group pog institut feasibl toxic efficaci common regimen high-dos chemoradiotherapi HD ct/rt autolog allogen marrow infus children metastat neuroblastoma nbl first second remiss period patient result treatment year HD ct/rt regimen melphalan dose total bodi irradi tbi Gy Gy dose twenty-thre patient irradi consist Gy dose diseas site autolog allogen autolog marrow fifty-four children first complet CR partial PR remiss second CR PR octob follow-up month children complic unknown caus continu remiss first remiss treatment year actuari event-fre surviv ef probabl first CR SE first PR SE second CR SE second PR SE probabl ef remiss number second interv diagnosi HD ct/rt month month tbi dose Gy Gy encourag result select treatment patient nbl diseas pace